2011 - ISBTS 2011 Symposium


This page contains exclusive content for the member of the following sections: TTS, ITA. Log in to view.

Plenary Session I: Disappearing PNLD? + Oral Communications 1

3.105 - Effect of multisource lipid (SMOF) on polyunsaturated fatty acid (PUFA) composition of red blood cell (RBC) membranes, and changes occurring after small bowel transplantation (SBTx)

Presenter: Sue, Beath, Birmingham, United Kingdom
Authors: Tulpesh Patel2, Girish Gupte1, Deirdre Kelly1, Kelly Guthrie1, Sue Protheroe1, Jaswant Sira1, JWL Puntis4, Gareth Griffiths3, Joel Talcott2, Sue Beath1

105
Effect of multisource lipid (SMOF) on polyunsaturated fatty acid (PUFA) composition of red blood cell (RBC) membranes, and changes occurring after small bowel transplantation (SBTx)

Tulpesh Patel2, Girish Gupte1, Deirdre Kelly1, Kelly Guthrie1, Sue Protheroe1, Jaswant Sira1, JWL Puntis4, Gareth Griffiths3, Joel Talcott2, Sue Beath1

1Birmimgham Children’s Hospital, Birmimgham, United Kingdom; 2Department of Life & Health Sciences, Aston University, Birmimgham, United Kingdom; 3Department of Chemical Engineering and Applied Chemistry, Aston University, Birmimgham, United Kingdom; 4The General Infirmary Leeds, Leeds, United Kingdom

The use of lipids in children with intestinal failure has been linked with liver disease and patients who show signs of liver disease have been given Soya-MCT-Oliveoil-Fishoil (SMOF) - a lipid high inw3 fatty acids (FA).

Aim: to measure FA profiles before and12 months post-Tx.

Methods: FAs were extracted from RBCs and analysed by Gas Chromatography-Flame Ionised Detection in two boys (A aged 12, B age 14) who received an isolated SBTx, and combined liver/SBTx respectively.  Intake of FAs was calculated from PN prescription and dietetic records.

Results: Pre-Tx both patients were on identical PN (SMOF 2g/kg/day).  Post-Tx patientA received Peptamen Junior, and patientB Osmolite 1.5cal, neither feed contained PUFAs (Arachidonic acid (AA) or Docasahexaneoic acid (DHA).  The ratio of w6:w3 FA intake increased from 2.5 in SMOF to 7 (Peptamen) and 4.5 (Osmolite) and the intake of EFAs went from 21% in SMOF to 24% and 18% respectively.  The RBC measurements showed that the ratio of w6:w3 FA remained stable pre and post-Tx (patient A w6:w3 = 1.4 to 1.14 and patient B 1.86 to 1.94) although both were above the reference range (1.01 to 1.19).  AA and DHA % levels were high pre-Tx (patientA = 11.29 and 12.14; patientB = 11.05 and 11.48) and remained high post-Tx especially for pro-inflammatory AA (patientA = 11.40 and 9.94); patientB = 10.94 and 10.21) compared to the reference range (AA=8.04 -10.71; DHA=7.65-10.19). 

Conclusion: Both children were able synthesis PUFAs satisfactorily from their enteral food source and maintained w6:w3 biomarker values comparable to age-matched controls.  We conclude that the provision of AA and DHA in PN is not necessary in older children.  The reason for the persistently high level of AA in these two patients is unclear and may relate to sepsis before and after transplant.


Important Disclaimer

By viewing the material on this site you understand and accept that:

  1. The opinions and statements expressed on this site reflect the views of the author or authors and do not necessarily reflect those of The Transplantation Society and/or its Sections.
  2. The hosting of material on The Transplantation Society site does not signify endorsement of this material by The Transplantation Society and/or its Sections.
  3. The material is solely for educational purposes for qualified health care professionals.
  4. The Transplantation Society and/or its Sections are not liable for any decision made or action taken based on the information contained in the material on this site.
  5. The information cannot be used as a substitute for professional care.
  6. The information does not represent a standard of care.
  7. No physician-patient relationship is being established.

Social

Contact

Staff Directory
+1-514-874-1717
info@tts.org

Address

The Transplantation Society
International Headquarters
740 Notre-Dame Ouest
Suite 1245
Montréal, QC, H3C 3X6
Canada